“we remain on track to provide an upgrade of our dose optimization studies of danuglipron in the first quarter of this year.”

In context

“e in second-line-plus non-small cell lung cancer where the unmet need is significant. We have a robust clinical development program aimed at expanding are indications in multiple myeloma, and this year, we anticipate the readout of a Phase 3 study in double class exposed relapsed refractory multiple myeloma, that, if successful and approved, will triple the addressable population versus the currently approved indication. In vaccines, we expect to start the Phase 3 study this year for our PCV-25 candidate covering 25 serotypes. This is important foundational work that could help us bridge to and accelerate progress with our fifth generation PCV candidate covering more than 30 serotypes. This year, we also expect to start a Phase 3 study for our C. diff vaccine candy. In internal medicines, we remain on track to provide an upgrade of our dose optimization studies of danuglipron in the first quarter of this year. For ponsegromab, we expect to start a pivotal study this year in cancer caked ibuzatrelvir, our second-generation COVID-19 oral antiviral candidate, continues its Phase 3 study. Within I&I, we continue to progress a portfolio of medicines that include two potential first-in-class tri-specific antibodies currently in Phase 2. Now let's discuss our commercial strategy. 2024 was a strong year of commercial execution and we are pleased with our progress in improving performance of our newly launched products and gaining and maintaining market share for several of our core brands. I will start by highlighting the strength and impact of our oncology portfolio. Padcev plus pembrolizumab is an important growth driver as it has already become the #1 prescribed first-line treatment for locally adva”